Stock XERS XERIS BIOPHARMA HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Xeris Biopharma Holdings, Inc.

Equities

XERS

US98422E1038

Market Closed - Nasdaq
Other stock markets
 03:59:51 2024-05-29 pm EDT 		5-day change 1st Jan Change
1.935 USD +0.78% Intraday chart for Xeris Biopharma Holdings, Inc. -3.73% -17.66%
May. 09 Transcript : Xeris Biopharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09 Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Xeris Biopharma: Q1 Earnings Snapshot
AQ
Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
BU
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
BU
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
BU
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BU
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
BU
Xeris Biopharma: Q4 Earnings Snapshot
AQ
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
BU
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
BU
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
BU
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
BU
Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab
BU
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BU
Xeris Biopharma Updates Its Outlook for 2023
BU
Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BU
Xeris Biopharma CEO unveils game-changing drug innovations and record financial success
AQ
Xeris Biopharma: Q3 Earnings Snapshot
AQ
Xeris Biopharma Reports Third Quarter 2023 Financial Results
BU
Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023
BU
Xeris Biopharma Announces Private Convertible Note Exchange Transactions
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XERS Stock
  4. News Xeris Biopharma Holdings, Inc.
  5. Press Releases